Tags Archive Navigation
icon
-
Media ReleaseNovartis resumes production and delivery of radioligand therapy medicines ahead of schedule
-
Media ReleaseNew Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
-
Media ReleaseNovartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
-
Media ReleaseNovartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
-
Media ReleaseNovartis presents new data in breast and prostate cancer at ESMO
-
Media ReleaseNovartis highlights depth of immunology pipeline with novel data at key upcoming international congresses
-
Media ReleaseNovartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
-
Media ReleaseNovartis announces tislelizumab demonstrated efficacy and tolerability in first-line advanced liver cancer in Phase III trial
-
Media ReleaseNovartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer
-
Media ReleaseNovartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
-
Media ReleaseNovartis maintains growth momentum and confirms FY’22 Group guidance
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 28
- › Next page